[go: up one dir, main page]

AU2002312897A1 - Drugs for the treatment of the alzheimer disease - Google Patents

Drugs for the treatment of the alzheimer disease

Info

Publication number
AU2002312897A1
AU2002312897A1 AU2002312897A AU2002312897A AU2002312897A1 AU 2002312897 A1 AU2002312897 A1 AU 2002312897A1 AU 2002312897 A AU2002312897 A AU 2002312897A AU 2002312897 A AU2002312897 A AU 2002312897A AU 2002312897 A1 AU2002312897 A1 AU 2002312897A1
Authority
AU
Australia
Prior art keywords
drugs
treatment
alzheimer disease
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002312897A
Inventor
Piero Del Soldato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Publication of AU2002312897A1 publication Critical patent/AU2002312897A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002312897A 2001-05-15 2002-05-10 Drugs for the treatment of the alzheimer disease Abandoned AU2002312897A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI000985A ITMI20010985A1 (en) 2001-05-15 2001-05-15 DRUGS FOR ALZHEIMER DISEASE
ITMI2001A000985 2001-05-15
PCT/EP2002/005165 WO2002092072A2 (en) 2001-05-15 2002-05-10 Drugs for the treatment of the alzheimer disease

Publications (1)

Publication Number Publication Date
AU2002312897A1 true AU2002312897A1 (en) 2002-11-25

Family

ID=11447649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002312897A Abandoned AU2002312897A1 (en) 2001-05-15 2002-05-10 Drugs for the treatment of the alzheimer disease

Country Status (3)

Country Link
AU (1) AU2002312897A1 (en)
IT (1) ITMI20010985A1 (en)
WO (1) WO2002092072A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
AU2003208525B9 (en) 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
CA2487414A1 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP2005539089A (en) 2002-07-03 2005-12-22 ニトロメッド インコーポレーティッド Nitrosated non-steroidal anti-inflammatory compounds, compositions and methods of use
JP2005538110A (en) 2002-07-29 2005-12-15 ニトロメッド インコーポレーティッド Cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20040138296A1 (en) * 2002-08-12 2004-07-15 Pharmacia Corporation Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
ITMI20021861A1 (en) * 2002-08-29 2004-02-29 Nicox Sa NITROXIALKYL ESTER SYNTHESIS PROCESS OF CARBOXYLIC ACIDS, INTERMEDIATES THAT CAN BE USED IN THAT PROCEDURE AND THEIR PREPARATION.
US7585997B2 (en) * 2003-12-31 2009-09-08 Chesterford Enterprises Limited Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
BRPI0515218A (en) 2004-08-26 2008-07-08 Nicholas Piramal India Ltd compound, pharmaceutical composition, method for the treatment of a mammal or human, method of using the compound, new intermediates, use of the new intermediates, process for the preparation of a compound
GB0606015D0 (en) 2006-03-28 2006-05-03 Merck Sharp & Dohme therapeutic agents
US20100168228A1 (en) * 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
CA2692805A1 (en) 2007-07-09 2009-01-15 Nicox S.A. Use of nitric oxide releasing compounds in the treatment of chronic pain
CN101820755B (en) 2007-08-10 2013-05-15 巴赛尔·雷盖斯 Anti-inflammatory compounds and uses thereof
EP2378879A4 (en) 2008-12-16 2012-06-06 Merck Sharp & Dohme TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PT2699242T (en) 2011-04-19 2018-01-22 Alfama Inc Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (en) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドAlfama,Inc. Ruthenium monoxide releasing molecules and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
IT1256345B (en) * 1992-08-20 1995-12-01 NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
IT1256450B (en) * 1992-11-26 1995-12-05 Soldato Piero Del NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
IT1311924B1 (en) * 1999-04-13 2002-03-20 Nicox Sa PHARMACEUTICAL COMPOUNDS.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use

Also Published As

Publication number Publication date
ITMI20010985A1 (en) 2002-11-15
WO2002092072A2 (en) 2002-11-21
ITMI20010985A0 (en) 2001-05-15
WO2002092072A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AU2003219690A1 (en) Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AUPR610501A0 (en) Treatment of parasitic disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
AU2002359282A1 (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
AU2002316622A1 (en) Aminediols for the treatment of alzheimer's disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer's disease
AU2002309857A1 (en) Vaccines for the treatment of autoimmune disease
AU2002238991A1 (en) Novel drugs for preventing/treating immunopathic diseases
AU2002365654A1 (en) Treatment of diseases via the skin

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase